carrimycin
Term · Oncology and biomedicine · MLC-T-ONC-012319
A 16-membered macrolide antibiotic, with potential antibacterial and immunomodulatory activities. Upon administration, carrimycin targets and binds to bacterial ribosomes, thereby inhibiting protein synthesis. Carrimycin may be active against some Gram-positive bacteria and Mycobacterium tuberculosis. It may also have immunomodulatory activity, presumably through a different mechanism, which has not yet been characterized.
| Identifier | MLC-T-ONC-012319 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | shengjimycin; biotechspiramycin |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-012319",
"term": "carrimycin",
"field": "Oncology and biomedicine",
"definition": "A 16-membered macrolide antibiotic, with potential antibacterial and immunomodulatory activities. Upon administration, carrimycin targets and binds to bacterial ribosomes, thereby inhibiting protein synthesis. Carrimycin may be active against some Gram-positive bacteria and Mycobacterium tuberculosis. It may also have immunomodulatory activity, presumably through a different mechanism, which has not yet been characterized.",
"synonyms": [
"shengjimycin",
"biotechspiramycin"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/carrimycin/"
}
Record 4,284 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.